Getting Real: The Changing Tide on Real-World Evidence in Drug Development
NPC's Jennifer Graff will participate in a FierceBiotech panel discussion on using real-world evidence in the drug development process.
"
The 21st Century Cures Act sent a clear signal that regulators are recognizing the need for high-quality, real-world evidence (RWE) to inform decisions. How does that shift impact those in the biopharmaceutical sector driving the drug development process?
FiercePharma’s Senior Editor Carly Helfand will moderate a panel discussion with NPC Vice President of Comparative Effectiveness Research, Jennifer Graff, PharmD, and experts from Pfizer, Parexel, MIT NEWDIGS and Syneos Health. The panel will address the opportunities and challenges for companies, including how new technologies are allowing deeper analysis of real-world data sources, how companies are using RWE to enhance clinical trials, and the resources companies need to leverage RWE.
Register for the event on the FierceBiotech website.
"